15:00 , Jun 29, 2018 |  BC Week In Review  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies. Agios...
20:18 , Jun 27, 2018 |  BC Extra  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies. Agios...
16:47 , Jun 8, 2018 |  BC Week In Review  |  Company News

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop and...
22:12 , Jun 4, 2018 |  BC Extra  |  Company News

CStone gains China rights to Blueprint programs

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...
13:27 , Jun 2, 2018 |  BC Extra  |  Clinical News

Loxo reports updated Phase I data for RET inhibitor

Loxo Oncology Inc. (NASDAQ:LOXO) reported updated response data on Saturday at the American Society of Clinical Oncology meeting in Chicago from the Phase I LIBRETTO-001 trial evaluating its ret proto-oncogene (RET) inhibitor LOXO-292 to treat...
19:11 , May 18, 2018 |  BC Week In Review  |  Clinical News

Loxo reports Phase I RET inhibitor data

Loxo Oncology Inc. (NASDAQ:LOXO) reported response data from an open-label, international Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. The data were released in an abstract ahead of the...
14:37 , May 17, 2018 |  BC Extra  |  Clinical News

Loxo gains on Phase I RET inhibitor data

Loxo Oncology Inc. (NASDAQ:LOXO) gained $28.03 (20%) to $167.53 Thursday after reporting response data from a Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. The data were released late...
17:41 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Blueprint reports early data for RET inhibitor

Blueprint Medicines Corp. (NASDAQ:BPMC) reported data from the Phase I ARROW trial of BLU-667 to treat ret proto-oncogene (RET)-altered solid tumors. BLU-667 is a RET inhibitor. Among 14 evaluable patients with RET-altered non-small cell lung cancer...
20:08 , Apr 16, 2018 |  BC Extra  |  Clinical News

Blueprint reports early data for RET inhibitor

Blueprint Medicines Corp. (NASDAQ:BPMC) reported data from the Phase I ARROW trial of BLU-667 to treat ret proto-oncogene (RET)-altered solid tumors. BLU-667 is a RET inhibitor. Among 14 evaluable patients with RET-altered non-small cell lung cancer...
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...